UBS Group Downgrades Agios Pharmaceuticals (AGIO) to Market Perform

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by research analysts at UBS Group from an “outperform” rating to a “market perform” rating in a research report issued on Wednesday, The Fly reports.

Several other research analysts have also issued reports on AGIO. ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Royal Bank of Canada increased their target price on Agios Pharmaceuticals to $91.00 and gave the stock an “outperform” rating in a research report on Thursday, January 18th. They noted that the move was a valuation call. BidaskClub raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, January 16th. Zacks Investment Research raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 target price for the company in a research report on Tuesday, January 16th. Finally, Oppenheimer set a $83.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, January 1st. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $77.64.

Agios Pharmaceuticals (AGIO) traded down $0.40 during midday trading on Wednesday, reaching $76.53. The company’s stock had a trading volume of 531,500 shares, compared to its average volume of 848,348. Agios Pharmaceuticals has a 1-year low of $45.11 and a 1-year high of $82.96. The stock has a market cap of $4,285.58, a PE ratio of -12.21 and a beta of 2.12.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The business had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $12.65 million. During the same quarter last year, the business posted ($1.34) EPS. The company’s quarterly revenue was down 56.7% compared to the same quarter last year. equities analysts expect that Agios Pharmaceuticals will post -6.59 earnings per share for the current fiscal year.

In related news, insider Scott Biller sold 2,146 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $60.79, for a total transaction of $130,455.34. Following the completion of the transaction, the insider now owns 8,410 shares of the company’s stock, valued at approximately $511,243.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Corp /De/ Celgene acquired 851,154 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, January 23rd. The shares were bought at an average cost of $67.00 per share, with a total value of $57,027,318.00. Following the transaction, the insider now owns 1,374,599 shares in the company, valued at $92,098,133. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 183,114 shares of company stock valued at $13,866,025. 5.43% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Agios Pharmaceuticals by 23.8% during the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock valued at $165,401,000 after purchasing an additional 617,379 shares during the last quarter. Capital International Investors boosted its stake in Agios Pharmaceuticals by 0.3% during the 3rd quarter. Capital International Investors now owns 3,138,131 shares of the biopharmaceutical company’s stock valued at $209,470,000 after purchasing an additional 8,294 shares during the last quarter. State Street Corp boosted its stake in Agios Pharmaceuticals by 8.1% during the 2nd quarter. State Street Corp now owns 1,302,966 shares of the biopharmaceutical company’s stock valued at $67,036,000 after purchasing an additional 97,220 shares during the last quarter. First Trust Advisors LP boosted its stake in Agios Pharmaceuticals by 26.3% during the 4th quarter. First Trust Advisors LP now owns 813,647 shares of the biopharmaceutical company’s stock valued at $46,516,000 after purchasing an additional 169,331 shares during the last quarter. Finally, Alkeon Capital Management LLC purchased a new stake in Agios Pharmaceuticals during the 3rd quarter valued at $30,489,000. 82.74% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/14/ubs-group-downgrades-agios-pharmaceuticals-agio-to-market-perform.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

The Fly

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply